Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
作者： A D Seidman , D Hochhauser , M Gollub , B Edelman , T J Yao
DOI: 10.1200/JCO.1996.14.6.1877
关键词:
摘要: PURPOSEA phase II trial of paclitaxel infused over 96 hours in patients with metastatic breast cancer demonstrated disease progression (PD) during short-infusion taxane treatment was performed to evaluate schedule-dependent activity prolonged drug exposure. The tolerability this strategy and its pharmacokinetic profile pharmacodynamic correlates were also investigated.PATIENTS AND METHODSPaclitaxel administered 26 at 120 140 mg/m2 intravenously hours. Twenty-three had PD while receiving prior 3-hour paclitaxel, two 1-hour docetaxel, one infusions docetaxel then paclitaxel. Twenty-one (81%) no response the short infusion (primary resistance) five (19%) partial responses (PRs) brief duration before (secondary resistance). Plasma concentrations assessed 24, 48, 72, hours.RESULTSAfter delivery 195 cycles, seven of...
sci-hub.se 参考文章(25)
A D Seidman, A Tiersten, C Hudis, M Gollub, S Barrett, T J Yao, J Lepore, T Gilewski, V Currie, J Crown, Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 13, pp. 2575- 2581 ,(1995) , 10.1200/JCO.1995.13.10.2575
A. D. Seidman, R. Portenoy, T. -J. Yao, J. Lepore, E. K. Mont, J. Kortmansky, N. Onetto, L. Ren, J. Grechko, M. Beltangady, J. Usakewicz, M. Southrada, C. Houston, M. McCabe, R. Salvaggio, H. Thaler, L. Norton, Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor Journal of the National Cancer Institute. ,vol. 87, pp. 1316- 1322 ,(1995) , 10.1093/JNCI/87.17.1316
Lisa M. Adler, Thomas J. Herzog, Sybilann Williams, Janet S. Rader, David G. Mutch, Analysis of exposure times and dose escalation of paclitaxel in ovarian cancer cell lines. Cancer. ,vol. 74, pp. 1891- 1898 ,(1994) , 10.1002/1097-0142(19941001)74:7<1891::AID-CNCR2820740711>3.0.CO;2-K
John D. Hainsworth, F. Anthony Greco, Paclitaxel administered by 1‐hour infusion. Preliminary results of a phase 1/11 trial comparing two schedules Cancer. ,vol. 74, pp. 1377- 1382 ,(1994) , 10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U
David R. Spriggs, Carlo Tondini, Taxol administered as a 120 hour infusion. Investigational New Drugs. ,vol. 10, pp. 275- 278 ,(1992) , 10.1007/BF00944181
Radhey S. Gupta, Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies. Journal of Cellular Physiology. ,vol. 114, pp. 137- 144 ,(1983) , 10.1002/JCP.1041140122
Lloyd R. Kelland, George Abel, Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemotherapy and Pharmacology. ,vol. 30, pp. 444- 450 ,(1992) , 10.1007/BF00685595
Narima M. Lopes, Earl G. Adams, Thomas W. Pitts, Bijoy K. Bhuyan, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemotherapy and Pharmacology. ,vol. 32, pp. 235- 242 ,(1993) , 10.1007/BF00685842
JE Liebmann, JA Cook, C Lipschultz, D Teague, J Fisher, JB Mitchell, Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. British Journal of Cancer. ,vol. 68, pp. 1104- 1109 ,(1993) , 10.1038/BJC.1993.488
L. Gianni, E. Munzone, G. Capri, F. Villani, C. Spreafico, E. Tarenzi, F. Fulfaro, A. Caraceni, C. Martini, A. Laffranchi, P. Valagussa, G. Bonadonna, Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. Journal of the National Cancer Institute. ,vol. 87, pp. 1169- 1175 ,(1995) , 10.1093/JNCI/87.15.1169